Mycotopia Therapies, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TPIA research report →
Companywww.mycotopiatherapies.com
Mycotopia Therapies, Inc. focuses on psychedelics for the treatment of mental health issues. It provides psychedelic therapies for the treatment of post-traumatic stress disorder, severe anxiety, depression, palliative care, and serotonin syndrome.
- CEO
- Benjamin Kaplan
- IPO
- 2006
- Employees
- 1
- HQ
- Aventura, FL, US
Price Chart
Valuation
- Market Cap
- $113.83K
- P/E
- -0.09
- P/S
- 201.84
- P/B
- -0.05
- EV/EBITDA
- -1.14
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -7732.39%
- Op Margin
- -84501.74%
- Net Margin
- -101500.27%
- ROE
- 55.77%
- ROIC
- 68.91%
Growth & Income
- Revenue
- $2.18K · 0.00%
- Net Income
- $-2,215,751 · -19.88%
- EPS
- $0.00 · 100.00%
- Op Income
- $-1,844,673
- FCF YoY
- -76.90%
Performance & Tape
- 52W High
- $0.18
- 52W Low
- $0.01
- 50D MA
- $0.02
- 200D MA
- $0.03
- Beta
- 2.56
- Avg Volume
- 173.85K
Get TickerSpark's AI analysis on TPIA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our TPIA Coverage
We haven't published any research on TPIA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TPIA Report →